Replies to post #10907 on Sorrento Therapeutics Inc (SRNE)

[cheynew]

1:15p ET 8/4/2021 - Dow Jones
Sorrento Up 2% on Salicyn-30 Article
Mentioned: SRNE

By Josh Beckerman

Sorrento Therapeutics Inc. shares were recently up 2% to $8.35 after the company discussed an article about "promising results" for Salicyn-30 in a rodent model.

Sorrento, in collaboration with The Scripps Research Institute of La Jolla, said the American Chemical Society published "Salicylanilides Reduce SARS-CoV-2 Replication and Suppress Induction of Inflammatory Cytokines in a Rodent Model."

An analysis in a prophylactic mouse model of SARS-CoV-2 infection "demonstrated that Salicyn-30 can potentially reduce viral loads, modulate key cytokines, and mitigate severe weight loss involved in Covid-19 infections," the company said.

Write to Josh Beckerman at [e-mail]

(END) Dow Jones Newswires

August 04, 2021 13:15 ET (17:15 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.

[1776club]

Yup, but we are in Rats and then there is this; Published March 8
Dr. Marc Siegel says a new experimental pill developed to treat COVID-19 could be the "holy grail of therapeutics" used against the virus. First-stage testing of Molnupiravir, developed by Merck and Ridgeback Biotherapeutics, showed promising signs of effectiveness in reducing the virus in patients.

What stage are we in again? Oh yea, Preclinical.
What stage are they in again?
Active, not recruiting Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
Coronavirus Disease (COVID-19)
Drug: Molnupiravir
Drug: Placebo
Phase 2
Phase 3 August 10, 2021

[dia76ca]

All studies start with mice. So far Salicyn-30 looks interesting. There are lots of anti-virals out there. Are they better? Are they as good? This is what interests me..."Moreover, based on their mechanism of action, Salicyn-30 and other lead compounds may be equally effective against RECENT EMERGING SARS-CoV-2 VARIANTS. The combination of anti-SARS-CoV-2 activity, cytokine inhibitory activity, VARIANT INDIFFERENCE and a previously established favorable pharmacokinetic profile for the lead Salicyn-30 renders salicylanilides in general, and Salicyn-30 in particular, as promising therapeutics for COVID-19."
Time will tell!

The full paper is available to read at: https://pubs.acs.org/doi/full/10.1021/acsinfecdis.1c00253.